Novo Nordisk Raises 2026 Outlook Again on Wegovy Pill Demand
Novo Nordisk cited stronger-than-expected performance by its oral Wegovy as it raised its 2026 outlook for the third time this year.
Related stories
StubHub Raises Full-Year Gross Merchandise Sales Outlook to $10.3 Billion
StubHub raised its full-year gross merchandise sales outlook to $10.3 billion from $10.1 billion.
M impact | EARNINGS | Nov 15, 2026, 02:03 AM UTC
Merlin Properties Raises 2026 FFO Guidance to EUR 0.58 per Share
Merlin Properties raised its 2026 FFO guidance to EUR 0.58 per share and updated its strategy for its 704 MW data center portfolio.
M impact | EARNINGS | Nov 14, 2026, 08:03 PM UTC
Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound
The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC
Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds
Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC
China to Add JW Therapeutics’ CAR-T Therapy to State Insurance
China’s National Healthcare Security Administration says JW Therapeutics’ CAR-T therapy will be added to the state-run health insurance scheme.
L impact | REGULATION | Nov 14, 2026, 03:03 AM UTC
China to Add JW Therapeutics CAR-T Therapy to State Health Insurance
China's National Healthcare Security Administration says JW Therapeutics' CAR-T therapy will be added to the state-run health insurance scheme.
M impact | REGULATION | Nov 14, 2026, 03:03 AM UTC